Senate Bill 517 would create a new Article 11C in Chapter 131E of the North Carolina General Statutes to regulate certain 340B covered entities, primarily hospitals and other entities participating in the federal 340B Drug Pricing Program. Part 1 would prohibit a covered entity from charging more than its acquisition cost for a 340B drug when dispensing, administering, or otherwise delivering that drug to a patient. Any violation would be treated as an unfair or deceptive trade practice under state law, exposing the entity to the enforcement and penalty provisions of Chapter 75.
Part 2 would impose extensive annual transparency and reporting requirements on covered entities, beginning with reports due October 1, 2026. Covered entities would have to report acquisition costs, payments received, prescription volumes, charity care costs, use of sliding fee scales, payments to contract pharmacies and third-party administrators, and information about in-state and out-of-state contract pharmacies. The Department would be required to post the reports publicly on its website, creating a public-facing disclosure regime for 340B program participation and related financial arrangements.
Impact
The bill would add new state-level pricing and disclosure rules on top of the federal 340B Drug Pricing Program, affecting hospitals and other covered entities that purchase discounted outpatient drugs under federal law. It would limit what those entities may collect from patients for 340B drugs, require detailed annual reporting to the Department, and make the reports publicly available. The bill also incorporates Chapter 75 unfair trade practice remedies, which could increase litigation and enforcement exposure for covered entities that fail to comply.
Sentiment
No committee transcripts or recorded votes were provided, so there is no direct evidence of debate or formal support/opposition in the materials supplied. Based on the bill text alone, the measure appears designed to promote lower patient costs and greater transparency, suggesting a consumer- and accountability-focused policy rationale. At the same time, the detailed reporting obligations and pricing restrictions indicate the bill would likely be viewed as burdensome by hospitals and other 340B participants.
Contention
The main points of contention are likely to be whether North Carolina should cap patient charges at acquisition cost for 340B drugs and whether the state should require extensive disclosure of 340B finances, contract pharmacy arrangements, and third-party payments. Hospitals and covered entities may argue that the bill interferes with program administration, increases compliance costs, and could affect charity care or access to services. Supporters would likely emphasize patient affordability, transparency, and scrutiny of contract pharmacy and administrative arrangements, especially where 340B savings are not clearly passed through to patients.